220 related articles for article (PubMed ID: 11970748)
1. Rationale and use of epirubicin-based therapy in the adjuvant setting.
Mouridsen HT
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S34-40. PubMed ID: 11970748
[TBL] [Abstract][Full Text] [Related]
2. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
4. Overview of epirubicin-based adjuvant therapy in breast cancer.
Untch M; von Koch F; Kahlert S; Konecny G
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S41-5. PubMed ID: 15959941
[TBL] [Abstract][Full Text] [Related]
5. Role of epirubicin in advanced breast cancer.
Conte PF; Gennari A; Landucci E; Orlandini C
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S46-51. PubMed ID: 11970749
[TBL] [Abstract][Full Text] [Related]
6. The expanding role of epirubicin in the treatment of breast cancer.
Glück S
Cancer Control; 2002; 9(2 Suppl):16-27. PubMed ID: 11965227
[TBL] [Abstract][Full Text] [Related]
7. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
Davidson NE
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
9. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
11. [Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Lagha A; Chraiet N; Labidi S; Krimi S; Ayadi M; Gligorov J; Boussen H
Bull Cancer; 2013 May; 100(5):465-71. PubMed ID: 23613145
[TBL] [Abstract][Full Text] [Related]
12. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Nagykálnai T
Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
14. A systematic overview of chemotherapy effects in breast cancer.
Bergh J; Jönsson PE; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
[TBL] [Abstract][Full Text] [Related]
15. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
[TBL] [Abstract][Full Text] [Related]
16. Epirubicin in combination with the taxanes.
Trudeau M; Pagani O
Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
[TBL] [Abstract][Full Text] [Related]
17. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
Nabholtz JM; Riva A
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S7-14. PubMed ID: 11970739
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel-anthracycline combinations in metastatic breast cancer.
Nabholtz JM
Breast Cancer Res Treat; 2003; 79 Suppl 1():S3-9. PubMed ID: 12868800
[TBL] [Abstract][Full Text] [Related]
19. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]